Myoconda, the company's lead product, is a combination of the antibiotics rifabutin, clarithromycin and clofazimine envisaged as a new treatment for Crohn's Disease.
Myoconda is a combination of the antibiotics rifabutin, clarithromycin and clofazimine envisaged as a new treatment for Crohn's Disease. Myoconda was the company's lead product.